Erlotinib hydrochloride

This publication has 11 references indexed in Scilit:

• Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
  JNCI Journal of the National Cancer Institute, 2005
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer
  Journal of Clinical Oncology, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Issues and progress with protein kinase inhibitors for cancer treatment
  Nature Reviews Drug Discovery, 2003
• Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy
  The Oncologist, 2002
• Lung cancer: A review
  American Journal of Health-System Pharmacy, 2002
• Untangling the ErbB signalling network
  Nature Reviews Molecular Cell Biology, 2001
• Epidermal growth factor-related peptides and their receptors in human malignancies
  Published by Elsevier ,2000